Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Cellular and targeted therapies for Hodgkin lymphoma

Pauline Brice • 26 Mar 2019
EBMT 2019
Hodgkin Lymphoma Lymphoma Brentuximab vedotin Checkpoint inhibitors

Here, Pauline Brice, MD, PhD, of Hopital Saint-Louis, Paris, France, talks about the new targeted and cellular therapies for Hodgkin lymphoma. Dr Brice was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Pauline Brice

1:13
Treatment combinations in Hodgkin lymphoma
Pauline Brice • 26 Mar 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals